A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in ...

The State of Kansas announced an $895 million capital expansion project at the Merck Animal Health manufacturing facility in ...

Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, manufacturing and warehouse capabilities to produce next-generation biologics and ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing foreign-exchange effects and uncertainty over tariffs.

Imec and Merck have announced a strategic partnership to develop an advanced MicroPhysiological Systems (MPS) platform.

Merck KGaA (MKGAF) reports robust revenue and EBITDA growth, while navigating macroeconomic headwinds and adjusting guidance ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...